Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype
- Citation:
- Leuk Lymphoma vol 55 (7) 1523-1532
- Year:
- 2014
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 3
- Parents:
- 355
- Children:
- None
- Pharmas:
- Grants:
- CA114737, U10 CA180861, U10 CA021115, U10 CA031946, CA021115, U10 CA037403, R01 CA056771, U10 CA180820, U24 CA114737, U10 CA180888, CA31946, CA56771
- Corr. Author:
- Authors:
- Xavier Poiré Barry K. Moser Robert E. Gallagher Kristina Laumann Clara D. Bloomfield Bayard L. Powell Gregory Koval Kabir Gulati Nicholas Holowka Richard A. Larson Martin S. Tallman Frederick R. Appelbaum Dorie Sher Cheryl Willman Elisabeth Paietta Wendy Stock
- Networks:
- Study
- CALGB-9710
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Acute promyelocytic leukemia, arsenic trioxide, FLT3 mutations, mutant level, complex karyotype, prognosis